Best ADC (Antibody-Drug Conjugate) CDMOs in China

HPAPI containment

Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work.

Linker-payload chemistry on file

Match the CDMO's payload + linker experience to your program. MMAE / vc-MMAE is the most common; PBDs, calicheamicin, Dxd-class topoI inhibitors, and TLR agonists each carry distinct handling and analytical demands.

Commercial bioconjugation track record

Has the CDMO conjugated a commercially-approved ADC? Track record on Polivy, Padcev, Trodelvy, Enhertu, Tivdak, Elahere, Adcetris, Mylotarg, Besponsa, Lumoxiti, Blenrep, etc. is a strong qualifying signal.

Integrated DS + DP

Bioconjugation produces ADC drug substance; you'll also need sterile fill-finish for drug product. Confirm whether the CDMO covers both or partners — both routes work, but integrated is faster on transfer.

Regulatory track record

Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

US sponsors evaluating Chinese CDMOs currently face two active US regulatory considerations. The DoD 1260H list designates named Chinese companies as "Chinese Military Companies" — WuXi AppTec was added in June 2026. Listing itself doesn't restrict commercial pharma work but affects federally-funded research access and creates procurement complications for sponsors with government contracts. The BioSecure Act is proposed federal legislation that would restrict federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies (specifically BGI, MGI, Complete Genomics, WuXi AppTec, and WuXi Biologics as of current drafts). The bill has not passed as of 2026-08 but has bipartisan support. CDMO Signal does not encode US political risk into the Signal Score — the composite reflects regulatory quality, operations, financial stability, and capacity. Sponsors evaluating a Chinese CDMO for US-supplying programs should evaluate US regulatory risk separately as a distinct decision layer.

Chinese CDMOs supplying US and European markets need active FDA and EMA GMP certifications on the specific facility. The FDA and EMA both conduct facility inspections in China, and Chinese CDMOs' inspection outcomes have generally improved over the past decade. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly. Chinese CDMOs with cross-jurisdictional certification rank higher on this pillar than domestic-market-only competitors. Cross-check with the US region ranking — Chinese CDMOs appearing on both rankings have demonstrated cross-jurisdictional inspection posture, which materially reduces regulatory risk for programs supplying US markets.

China's CDMO capability is strongest in biologics (both mAb and biosimilar), viral vectors (particularly AAV, with substantial commercial-scale capacity via WuXi Advanced Therapies and others), and mRNA (rapid post-COVID capacity build). Small molecule and API manufacturing capacity is also substantial but sits outside CDMO Signal's primary coverage focus. Cross-reference with modality pages to filter Chinese CDMOs by capability: biologics, AAV, mRNA, or the viral vector umbrella. Individual profile pages surface facility-level detail.

Who are the top ADC (Antibody-Drug Conjugate) CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked ADC (Antibody-Drug Conjugate) CDMOs include WuXi Biologics. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many ADC (Antibody-Drug Conjugate) CDMOs have FDA inspection records?

CDMO Signal tracks 0 ADC (Antibody-Drug Conjugate) CDMOs with FDA inspection records and 4 EMA/MHRA GMP certificates across the group.

What's the difference between an ADC CDMO and a biologics CDMO?

A biologics CDMO makes the naked antibody (drug substance). An ADC CDMO additionally handles the cytotoxic payload synthesis and the bioconjugation step under HPAPI containment. Some large CDMOs (Lonza, Catalent) do both; others specialize in conjugation only and source the antibody from a biologics partner.

Which CDMOs have made commercially-approved ADCs?

Several CDMOs have commercial ADC track records. The rankings above show our scored ADC players — Lonza (Polivy, Padcev), Catalent (multi-program commercial conjugation), Piramal, AGC Biologics, Samsung Biologics, WuXi Biologics, Charles River — with FDA inspection and GMP detail per profile.

What HPAPI containment level should an ADC CDMO have?

OEB-5 (sub-microgram per cubic meter occupational exposure band) is the standard floor for handling MMAE, MMAF, DM1, DM4, Dxd, PBDs, and calicheamicin-class payloads. Some legacy payloads can run in OEB-4 but commercial work is OEB-5.